Korro Bio Inc
KRRO33.840USD
+1.270+3.90%
收盘 11/07, 16:00（美东）报价延迟15分钟
317.79M总市值
亏损市盈率 TTM
关于 Korro Bio Inc 公司
Korro Bio, Inc. 是一家生物制药公司。该公司发现、开发和商业化基于编辑核糖核酸 (RNA) 的基因药物，从而能够治疗罕见和高度流行的疾病。该公司正在生成一系列差异化项目，旨在利用人体天然的 RNA 编辑过程来实现精确但短暂的单碱基编辑。通过编辑 RNA 而不是 DNA，该公司正在扩大基因药物的覆盖范围。其寡核苷酸促进的 RNA 编辑 (OPERA) 是 RNA 编辑的基础平台，旨在通过提供可以靶向特定 RNA 序列的寡核苷酸向导来编辑体内 RNA。该公司的首个开发候选药物 KRRO-110 正在开发中，作为 Alpha-1 抗胰蛋白酶缺乏症 (AATD) 的潜在治疗方法，具有改变疾病并提供差异化治疗选择的潜力。
Korro Bio Inc简介
公司代码KRRO
公司名称Korro Bio Inc
上市日期Oct 03, 2019
CEODr. Ram Aiyar, Ph.D.
员工数量104
证券类型Ordinary Share
年结日Oct 03
公司地址One Kendall Square. Building 600-700
城市CAMBRIDGE
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编02139
电话16174681999
网址https://www.korrobio.com/
公司代码KRRO
上市日期Oct 03, 2019
CEODr. Ram Aiyar, Ph.D.
Korro Bio Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Mr. Venkat Krishnamurthy, Ph.D.
Mr. Venkat Krishnamurthy, Ph.D.
Senior Vice President - Platform
Senior Vice President - Platform
--
--
Ms. Stephanie Engels
Ms. Stephanie Engels
Senior Vice President - People and Culture
Senior Vice President - People and Culture
--
--
Dr. Rachel Meyers, Ph.D.
Dr. Rachel Meyers, Ph.D.
Independent Director
Independent Director
--
--
Dr. Katharine (Kate) Knobil, M.D.
Dr. Katharine (Kate) Knobil, M.D.
Independent Director
Independent Director
--
--
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Mr. Venkat Krishnamurthy, Ph.D.
Mr. Venkat Krishnamurthy, Ph.D.
Senior Vice President - Platform
Senior Vice President - Platform
--
--
Ms. Stephanie Engels
Ms. Stephanie Engels
Senior Vice President - People and Culture
Senior Vice President - People and Culture
--
--
收入明细
FY2025Q2
FY2025Q1
FY2024
暂无数据
地区USD
名称
营收
占比
United States
1.46M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 8 小时前
更新时间: 8 小时前
持股股东
股东类型
持股股东
持股股东
占比
Atlas Venture
12.11%
New Enterprise Associates (NEA)
11.62%
Fidelity Management & Research Company LLC
6.81%
Driehaus Capital Management, LLC
6.19%
Platanus Investment LLC
5.75%
其他
57.53%
持股股东
持股股东
占比
Atlas Venture
12.11%
New Enterprise Associates (NEA)
11.62%
Fidelity Management & Research Company LLC
6.81%
Driehaus Capital Management, LLC
6.19%
Platanus Investment LLC
5.75%
其他
57.53%
股东类型
持股股东
占比
Investment Advisor
30.67%
Hedge Fund
27.09%
Venture Capital
23.72%
Investment Advisor/Hedge Fund
13.96%
Corporation
5.75%
Research Firm
1.37%
Individual Investor
0.42%
Private Equity
0.34%
Pension Fund
0.12%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
186
9.14M
97.37%
-1.25M
2025Q2
186
10.38M
110.55%
-200.85K
2025Q1
189
10.53M
112.24%
-76.97K
2024Q4
194
10.26M
109.50%
+485.90K
2024Q3
177
9.16M
98.29%
-245.98K
2024Q2
167
9.06M
97.57%
+507.87K
2024Q1
179
7.52M
93.89%
+737.20K
2023Q4
198
7.18M
91.01%
+1.51M
2023Q3
223
264.10K
35.84%
-47.15K
2023Q2
235
150.53K
21.10%
-156.09K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Atlas Venture
1.14M
12.11%
--
--
Jun 30, 2025
New Enterprise Associates (NEA)
1.09M
11.62%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
639.22K
6.81%
-4.05K
-0.63%
Jun 30, 2025
Driehaus Capital Management, LLC
580.86K
6.19%
-1.59K
-0.27%
Jun 30, 2025
Platanus Investment LLC
540.16K
5.75%
--
--
Apr 15, 2025
Point72 Asset Management, L.P.
540.07K
5.75%
+19.18K
+3.68%
Jun 30, 2025
Cormorant Asset Management, LP
465.00K
4.95%
+84.70K
+22.27%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
423.16K
4.51%
+15.35K
+3.76%
Jun 30, 2025
Invus Public Equities Advisors, LLC
418.83K
4.46%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
386.74K
4.12%
+4.94K
+1.29%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月2日 周日
更新时间: 11月2日 周日
机构名称
占比
iShares Micro-Cap ETF
0.07%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
SPDR Portfolio MSCI Global Stock Market ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
查看更多
iShares Micro-Cap ETF
占比0.07%
Avantis US Small Cap Equity ETF
占比0.02%
iShares Russell 2000 Value ETF
占比0.02%
ProShares UltraPro Russell2000
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
iShares Russell 2000 ETF
占比0.01%
Global X Russell 2000 ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
SPDR Portfolio MSCI Global Stock Market ETF
占比0%
Invesco Dorsey Wright SmallCap Momentum ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
公告日期
类型
比率
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
